Clinically Meaningful Improvements in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab who did not Achieve Clear or Almost Clear Skin at Week 16

Abstract Introduction Investigator’s Global Assessment (IGA) of clear/almost clear (0/1) skin is a high standard to achieve after 16 weeks of treatment for patients with moderate-to-severe atopic dermatitis (AD) and does not capture clinically meaningful responses in other patient domains, such as i...

Full description

Bibliographic Details

Published in:	Dermatology and Therapy
Main Authors:	Amy S. Paller, Andrew Blauvelt, Weily Soong, H. Chih-ho Hong, Marie L. A. Schuttelaar, Shannon K. R. Schneider, Eric L. Simpson
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2025-07-01
Subjects:	Adolescent Clinically meaningful responses ECZTRA Phase 3 Post hoc Tralokinumab
Online Access:	https://doi.org/10.1007/s13555-025-01484-1